07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

Breckenridge sales and marketing update

Breckenridge launched azelastine nasal solution, a generic of Astelin from Meda AB (SSE:MEDAA, Solna, Sweden), in the U.S. The antihistamine is approved to treat seasonal allergic rhinitis in patients at least five years old and...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Breckenridge Pharmaceutical Inc, Teva, Natco cancer news

Teva’s Cephalon Inc. subsidiary filed suit against Breckenridge and partner Natco in the U.S. District Court for the District of Delaware alleging Breckenridge’s ANDA for a generic version of Cephalon’s Treanda bendamustine infringes U.S. Patent...
08:00 , Dec 13, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Natural cytotoxicity triggering receptor 1 (NCR1; NKP46; CD335); natural killer p30 receptor (NKp30; NCR3; CD337) Mouse and cell culture studies suggest inhibiting NCR1...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Breckenridge Pharmaceuticals Inc., Synthon Pharmaceuticals Inc., Watson, Aurobindo, Dr. Reddy's, Mylan, Novartis, Ranbaxy, Takeda, Teva, Torrent, Wockhardt endo

Takeda settled patent suits filed against companies that submitted ANDAs for generic versions of diabetes drugs Actos pioglitazone, ACTOplus met pioglitazone/metformin and duetact pioglitazone/glimepiride. Takeda granted Teva rights to an authorized generic version of Actos...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Clinical News

Sirtris preclinical data

Mice on high-fat diets that received SRT1720 remained lean while consuming the same number of calories as untreated animals. Those that received the highest dose of the small-molecule SIRT1 activator had no weight gain over...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Clinical News

Genaera preclinical data

In diet-induced obese mice, MS-1436 significantly improved glucose tolerance and reduced plasma insulin levels after 4 once-weekly treatments. In hyperglycemic mice, MIS-1436 significantly improved fasting blood glucose and glucose tolerance after 122 days of once-weekly...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Clinical News

Compugen preclinical data

In a mouse model of peritoneal inflammation, CGEN-54 reduced macrophage infiltration and inhibited monocyte migration. CGEN-54 is a truncated variant of monocyte chemoattractant protein-1 ( MCP-1 ) that inhibits the MCP-1/ CCR2 pathway. Data were...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In a mouse model of hypercholesterolemia, siRNA led to a durable silencing effect of the apolipoprotein B (apoB) gene. A systemic delivery of short interfering RNAs (siRNAs) in the mice fed with high fat diets...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In a mouse model of respiratory syncytial virus (RSV), intranasal administration of RSV specific short interfering RNAs (siRNAs) specifically inhibited RSV infection. Data were presented at the Keystone Symposium meeting in Breckenridge. Alnylam Pharmaceuticals Inc....